$PDPG Performance Drink Group Signs JV LOI with New

New Post Public Reply Private Reply Replies (0) Message Board
luckystock
270
$PDPG Performance Drink Group Signs JV LOI with New European Partner Focused on R&D
PDPG Explores Heart- Healthy Ingredients Including a new Cannabis Ingredient Range

WHEAT RIDGE, CO / ACCESSWIRE / March 7, 2022 / Performance Drink Group, Inc. (OTC PINK DPG) ("Performance Drink" or the "Company" , a new force in the manufacturing of unique Sports Nutrition and Energy Drinks, today announces a signed Letter of Intent (the "LOI" toward the establishment of a joint venture (the "JV" with a new EU-based partner that specializes in Research & Development.

Further details about the JV will be released over coming days and weeks.

The JV exists to foster the development of patent-protected trade secrets related to both raw ingredients and production processes for the fast growing beverage marketplace, with a particular emphasis on the development of a new and unique portfolio of ingredients, supplements, and products capable of promoting heart health.

"The goal of this partnership is to target game-changing R&D rooted in a very broad-spectrum sampling of natural ingredients, including olives, nuts, honeys, and, of course, cannabis-based products," stated PDPG CEO David W. Lovatt, commenting from Portugal. "Once the definitive agreement has been signed by all parties, this venture stands to give Performance Drink Group access to stable, growing revenue streams spanning multiple continents capable of lasting long into the future underpinned by strong IP protection."

https://finance.yahoo.com/news/performance-dr...00888.html
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Understanding Rollins' Current Market Position and Outlook

Updated Category News Views 226

Analyzing Rollins Inc.'s Stock Performance As we look at the current performance of Rollins Inc. (NYSE: ROL), the shares are trading around $55.73, reflecting a decrease of 1.24% in the recent session. While the stock has dipped by 3.81% over the past month, it has impressively increased by 10.91% year-over-year. This presents a curious juxtaposition of short-term...

Continue Reading
Silver One Reports Major Mineral Resource Estimate for Candelaria

Updated Category News Views 199

Candelaria Project Mineral Resource Estimate Silver One Resources Inc. (OTCQX: SLVRF) has made a significant announcement regarding the completion of a mineral resource estimate for the Candelaria Project. This estimate is prepared in accordance with the National Instrument 43-101, ensuring that the resources are assessed with high standards of transparency and accuracy....

Continue Reading
Investors Alert: Zynex (ZYXI) Faces Serious Legal Scrutiny

Updated Category News Views 197

Legal Investigation into Zynex, Inc. The Law Offices of Frank R. Cruz have announced a crucial investigation regarding Zynex, Inc. (ZYXI) focused on potential violations of federal securities laws. This investigation comes as a response to significant concerns raised about the company's recent financial disclosures and their implications for investors. Understanding the...

Continue Reading
Understanding Rentokil Initial's Stock Valuation Insights

Updated Category News Views 100

Assessing Rentokil Initial's Stock Performance In the current trading session, Rentokil Initial Inc. (NYSE: RTO) shares are priced at $26.42, witnessing a notable increase of 1.46%. Over the past month, the stock has gained 1.40%, though it has faced a decline of 7.78% in the last year. This fluctuation raises questions among shareholders regarding its valuation, despite...

Continue Reading
Innovative Insights on Efzofitimod from aTyr Pharma's Recent Conference

Updated Category News Views 177

aTyr Pharma Highlights Efzofitimod at Key Conference At a significant scientific gathering, aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology firm known for its innovative therapeutic approaches, shared compelling data concerning efzofitimod. This presentation underlined important insights about the treatment of pulmonary sarcoidosis. The conference, which...

Continue Reading